FDA study finds Visian ICL offers good long-term BSCVA

Article

Over a five-year follow-up period the Visian implantable collamer lens (ICL) (STAAR Surgical) maintains a good level of best spectacle corrected visual acuity (BSCVA).

Over a five-year follow-up period the Visian implantable collamer lens (ICL) (STAAR Surgical) maintains a good level of best spectacle corrected visual acuity (BSCVA), according to results from the US multicentre FDA study, as reported by John Vukich of Madison, Wisconsin, USA.

A total of 248 patients implanted with the Visian ICL have been followed for four yeas and 335 have been followed for >5 years. The average preoperative myopia was -10.06 D.

At five years, 52.7% of eyes with a preoperative BSCVA of 20/20 or better achieved a UCVA of 20/20 or better and 91.2% achieved a UCVA of 20/40 or better. Over the five-year period, seven patients (1.3%) developed clinically significant anterior subcapsular cataracts, each requiring extraction. No other complications were reported.

The results of this FDA study indicate that the Visian ICL is safe and effective in maintaining BSCVA over a five-year period.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.